Ketamine Therapy: Benefits, Risks, Cost, and What to Expect

If you’re reading this, there’s a good chance you’ve already tried the standard playbook for depression or chronic pain: therapy, SSRIs, maybe SNRIs, possibly a mood stabilizer or two. And if those treatments worked well for you, that’s genuinely great. But for roughly 30% of people with major depression, the conventional medications simply don’t deliver meaningful relief. That’s not a personal failure. It’s a biological reality that’s driven researchers toward one of the most surprising treatment breakthroughs in modern psychiatry: ketamine therapy.

Ketamine was first synthesized in 1962 and approved by the FDA as an anesthetic in 1970. For decades, it was a workhorse in operating rooms and battlefield medicine. Then, in 2000, a landmark study by Berman et al. demonstrated something remarkable: a single sub-anesthetic dose of ketamine could lift severe depression within hours, not the weeks or months that conventional antidepressants require. That finding sent shockwaves through psychiatry and launched an entirely new chapter in mental health treatment.

Today, ketamine infusion therapy is offered in hundreds of clinics across the United States, and the FDA-approved nasal spray version (Spravato/esketamine) has made ketamine-based treatment accessible through insurance for the first time. But the field is complicated. There are multiple delivery methods, wildly different price points, varying levels of evidence for different conditions, and legitimate questions about safety and long-term use that deserve honest answers.

This guide walks through all of it. No hype, no fear-mongering. Just what the research actually shows, what treatment looks like in practice, and how to decide whether ketamine for depression or other conditions might be worth exploring for your situation.

How Ketamine Works: The Science Behind a Model Shift

Understanding why ketamine is genuinely different from traditional antidepressants requires a brief look under the hood. This isn’t just another drug that tweaks serotonin levels. Ketamine operates through fundamentally different mechanisms, which is why it can produce effects in hours that SSRIs take weeks to achieve.

NMDA Receptor Antagonism: The Primary Mechanism

Ketamine’s primary action is blocking NMDA (N-methyl-D-aspartate) receptors, which are glutamate receptors found throughout the brain. Glutamate is the brain’s main excitatory neurotransmitter, and it plays a critical role in neural communication, learning, and memory. By temporarily blocking certain NMDA receptors, ketamine triggers a cascade of downstream effects that are far more important than the blockade itself.

BDNF and Synaptogenesis: Rebuilding Neural Connections

When ketamine blocks NMDA receptors on inhibitory interneurons, it causes a surge of glutamate activity in other parts of the brain. This glutamate burst triggers the release of brain-derived neurotrophic factor (BDNF), a protein that acts as a kind of fertilizer for neurons. BDNF promotes the growth of new synaptic connections, a process called synaptogenesis. This is significant because chronic depression and stress physically damage synaptic connections, particularly in the prefrontal cortex. Ketamine essentially helps the brain repair and rebuild the wiring that depression has degraded.

Default Mode Network Disruption

The default mode network (DMN) is a brain network that’s active when you’re engaged in self-referential thinking: ruminating, worrying, replaying conversations, catastrophizing. In depression, the DMN tends to be hyperactive, trapping people in loops of negative self-focused thought. Ketamine temporarily disrupts DMN connectivity, which may explain the subjective experience many patients describe as a “reset” or a break from the relentless chatter of depression. This disruption appears to open a window of neuroplasticity during which the brain can form healthier patterns of connectivity.

Forms of Ketamine Therapy: IV, IM, Nasal Spray, and Oral

Not all ketamine therapy is the same. The delivery method affects how quickly the drug takes effect, how much reaches your brain (bioavailability), the intensity of the experience, and what it costs. Here’s a clear breakdown of each approach.

Comparison: Ketamine Delivery Methods

What the Evidence Actually Shows: Condition by Condition

The enthusiasm around ketamine is justified in some areas and gets ahead of the science in others. Here’s an honest assessment of where the evidence stands for each major condition, using a clear grading system.

Treatment-Resistant Depression – ESTABLISHED

This is where the evidence is strongest. Multiple randomized controlled trials, including the landmark Zarate et al. (2006) study, have demonstrated that a single IV ketamine infusion produces rapid antidepressant effects in 50-70% of patients with treatment-resistant depression. Response typically begins within 2-4 hours and peaks at 24 hours. A series of six infusions over 2-3 weeks produces more sustained improvement. The FDA approval of Spravato further validates the approach, with Phase 3 trials showing significant improvement compared to placebo in treatment-resistant populations. The main limitation: effects from a single infusion typically fade within 1-2 weeks without follow-up treatment, necessitating a maintenance protocol.

Suicidal Ideation (Rapid Reduction) – ESTABLISHED

One of ketamine’s most clinically significant properties is its ability to rapidly reduce suicidal thoughts, often within hours. A 2018 meta-analysis by Wilkinson et al. in the American Journal of Psychiatry confirmed that ketamine produced rapid anti-suicidal effects across multiple trials. In 2020, the FDA approved Spravato specifically for major depressive disorder with acute suicidal ideation or behavior. This matters enormously because no other psychiatric medication works this quickly for suicidality. SSRIs take weeks, and they actually carry a black-box warning for increased suicidal thoughts in the initial treatment period for younger patients. Ketamine fills a critical gap in acute psychiatric care.

PTSD – PROMISING

A growing body of evidence suggests ketamine can significantly reduce PTSD symptoms. Feder et al. (2014) published the first RCT showing ketamine’s efficacy for PTSD, and subsequent studies have supported these findings. A 2021 study in the Journal of Clinical Psychiatry demonstrated that repeated IV ketamine infusions produced sustained improvement in PTSD symptoms. The mechanisms likely involve ketamine’s ability to disrupt traumatic memory reconsolidation and promote neuroplasticity in fear-processing circuits. Several clinics now offer ketamine-assisted psychotherapy for PTSD, combining the drug’s neuroplastic window with targeted therapeutic work. More large-scale trials are underway.

Anxiety Disorders – PROMISING

Evidence for ketamine’s anxiolytic effects is encouraging but not yet definitive. Glue et al. (2017) found that ketamine significantly reduced anxiety in patients with generalized anxiety disorder and social anxiety disorder. Several studies have shown ketamine reduces anxiety symptoms alongside depression, though fewer trials have isolated anxiety as the primary outcome. The glutamatergic mechanism and DMN disruption provide a theoretical basis for anxiolytic effects. More dedicated anxiety-focused trials are needed.

Chronic Pain – PROMISING

Ketamine has a long history in pain management, and its NMDA receptor blockade makes it mechanistically well-suited for certain chronic pain conditions. Evidence is strongest for complex regional pain syndrome (CRPS), fibromyalgia, and neuropathic pain. A 2019 consensus statement from the American Society of Regional Anesthesia and Pain Medicine supports ketamine infusions for CRPS and other chronic pain syndromes when conventional treatments have failed. Higher doses are sometimes used for pain than for depression, and protocols differ significantly.

OCD – EARLY

Preliminary research shows intriguing results for obsessive-compulsive disorder. Rodriguez et al. (2013) demonstrated rapid OCD symptom reduction following a single ketamine infusion, and a few subsequent studies have supported these findings. However, the evidence base remains small, effects appear to be short-lived, and much larger trials are needed before ketamine can be considered a standard treatment for OCD. It remains an area of active investigation.

Evidence Grading Summary

The Dissociative Experience: What Ketamine Actually Feels Like

Let’s address the elephant in the room honestly: does ketamine get you high?

At therapeutic doses, ketamine produces a dissociative state that most patients describe as distinctly different from being “high” in the recreational sense. The experience typically includes:

• Altered perception of time and space – minutes may feel like hours, and the room may seem to shift or float
• A sense of detachment from the body – feeling like you’re observing yourself from a distance
• Visual and sensory changes – colors may appear more vivid, sounds may seem distant or amplified
• Emotional processing – some patients experience waves of emotion, insight, or a feeling of profound calm
• Mild nausea or dizziness – temporary and manageable, often treated with anti-nausea medication

Most patients describe the experience as “strange but not unpleasant.” Some find it deeply meaningful; others describe it as mildly disorienting and are simply glad when it’s over. Neither reaction predicts therapeutic outcome. Research suggests the dissociative experience may actually contribute to antidepressant effects by disrupting entrenched neural patterns, though this remains debated.

The critical distinction from recreational use: therapeutic doses (0.5 mg/kg IV for depression) are significantly lower than recreational doses, are administered in a controlled medical setting with monitoring, and are given as part of a structured treatment protocol. The context and intention are fundamentally different, and so is the experience.

Ketamine vs. Other Depression Treatments

How does ketamine stack up against other treatment options for depression? Here’s a side-by-side comparison to help put things in context.

Cost Breakdown: What Ketamine Therapy Actually Costs

The cost of ketamine therapy varies dramatically depending on the delivery method, geographic location, and whether insurance covers any portion. Here’s a realistic breakdown of what patients typically pay.

Insurance and Spravato: What to Know

Spravato (esketamine) is the only ketamine-based treatment with FDA approval for depression, which means it’s the only version that most insurance companies will cover. Many major insurers including Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare have coverage policies for Spravato, though they typically require prior authorization and documentation that you’ve failed at least two adequate antidepressant trials. Copays can range from $0 to $200+ per session depending on your plan. Janssen, the manufacturer, also offers a savings program that can reduce out-of-pocket costs.

For IV ketamine, most patients pay entirely out of pocket. Some clinics offer package pricing or payment plans. Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can often be used since ketamine infusions are a legitimate medical expense when prescribed by a physician.

Safety, Side Effects, and Contraindications

Ketamine has a well-established safety profile from decades of use in anesthesia, but therapeutic use for mental health involves specific considerations that patients should understand.

Common Side Effects (During and Shortly After Treatment)

• Dissociation – the most common and expected effect at therapeutic doses; resolves within 1-2 hours
• Elevated blood pressure – temporary increases of 15-25% are typical; this is why blood pressure monitoring is essential
• Nausea – occurs in roughly 10-15% of patients; can be managed with anti-nausea medication
• Dizziness and drowsiness – patients should not drive for the rest of the day after treatment
• Headache – mild and usually short-lived
• Blurred vision – temporary, resolves as the drug wears off

Addiction Potential: What the Evidence Shows

This is one of the most common and understandable concerns about ketamine therapy. Here’s what we know: ketamine does have abuse potential when used recreationally at high doses and high frequency. However, in the clinical therapeutic context, the risk of addiction is low. A 2017 review published in CNS Drugs found minimal evidence of dependence or abuse in patients receiving ketamine for depression at standard therapeutic doses and frequencies. The controlled setting, sub-anesthetic dosing, and supervised administration all significantly reduce risk compared to unsupervised recreational use. That said, patients with a history of substance use disorders should be carefully evaluated, and ongoing monitoring is appropriate.

Blood Pressure Monitoring

Temporary blood pressure elevation is one of the most clinically significant side effects of ketamine treatment. During an IV infusion, systolic blood pressure typically increases by 15-25 mmHg and usually peaks around 15-20 minutes into the infusion. In reputable clinics, blood pressure is checked before treatment, at regular intervals during the infusion, and before discharge. Patients with borderline or controlled hypertension can often still receive treatment with appropriate monitoring, but this needs to be assessed on an individual basis by the treating physician.

What to Expect: A Typical Ketamine Treatment Journey

Frequently Asked Questions About Ketamine Therapy

How quickly does ketamine work for depression?

Many patients notice a shift in mood within hours of their first IV infusion. However, the full therapeutic effect typically builds over the initial series of six treatments. Some patients feel dramatic relief after one session; others experience a more gradual improvement. The rapid onset, compared to the 4-8 weeks required for SSRIs, is one of ketamine’s most significant clinical advantages, particularly for patients in acute distress or experiencing suicidal thoughts.

How long do the effects of ketamine therapy last?

After a single infusion, antidepressant effects typically last 3-14 days. After a full initial series of six infusions, many patients experience benefits lasting weeks to months. Maintenance frequency varies widely between individuals. Some patients eventually achieve sustained remission and can discontinue treatment; others require ongoing maintenance sessions. Combining ketamine with psychotherapy appears to extend the duration of benefits.

Is ketamine therapy safe long-term?

Long-term safety data for repeated low-dose ketamine is still being gathered. Concerns include potential urinary tract effects (bladder irritation, seen primarily in heavy recreational users at much higher doses), cognitive effects, and the possibility of tolerance. Current evidence from clinical use suggests that at therapeutic doses and frequencies, serious long-term adverse effects are uncommon. However, this is an area where ongoing research and monitoring are important, and patients should have regular check-ins with their treatment team.

Can I take ketamine with my current antidepressants?

In most cases, yes. Ketamine works through different mechanisms than SSRIs, SNRIs, and most other antidepressants, so there is generally no need to stop your current medications before starting ketamine treatment. Some providers may adjust the dose of certain medications (particularly benzodiazepines or lamotrigine, which may dampen ketamine’s effects), but this should be done under medical supervision. Never stop or adjust medications without consulting your prescriber.

What’s the difference between ketamine and Spravato?

Generic ketamine (used in IV infusions) is a racemic mixture containing equal parts of two mirror-image molecules: S-ketamine and R-ketamine. Spravato contains only S-ketamine (esketamine) and is delivered as a nasal spray. Spravato is FDA-approved for treatment-resistant depression and requires administration in a certified healthcare setting. The clinical differences are debated: some providers believe the IV racemic mixture is more effective, while the convenience and insurance coverage of Spravato make it more accessible for many patients.

Will I be unconscious during ketamine treatment?

No. Therapeutic doses for depression are sub-anesthetic, meaning you remain conscious throughout the treatment. You’ll be aware of your surroundings, though your perception may be altered. You can typically communicate with your care team during the infusion. Some patients close their eyes and listen to music; others prefer to sit quietly. You will not be able to drive afterward and will need someone to take you home.

Is at-home ketamine (oral/sublingual) effective?

At-home oral/sublingual ketamine, typically prescribed through telehealth platforms, has lower bioavailability (~20-25%) than IV ketamine (~100%). This means less of the drug reaches the brain per dose. While many patients report benefit from oral ketamine, the evidence base is much smaller than for IV infusions, and the experience is generally milder. Oral ketamine may be a reasonable option for patients who cannot access or afford IV treatment, but it should not be considered equivalent in terms of potency or evidence.

Can ketamine help with chronic pain?

Yes, and ketamine has been used in pain management for decades. NMDA receptor blockade plays a key role in central sensitization, a process that amplifies pain signals in chronic pain conditions. Ketamine infusions for pain typically use higher doses and longer infusion times than those used for depression. The best evidence supports its use for complex regional pain syndrome (CRPS), fibromyalgia, and neuropathic pain. Some patients with chronic pain and co-occurring depression benefit from treatment that addresses both conditions simultaneously.

What should I look for in a ketamine clinic?

Look for clinics staffed by board-certified physicians (psychiatrists, anesthesiologists, or emergency medicine specialists), that perform complete intake evaluations, monitor vital signs during every session, use validated outcome measures (like PHQ-9 or MADRS) to track progress, have clear protocols for adverse events, and are transparent about pricing and what is or isn’t included. Avoid clinics that guarantee results, skip medical screening, or seem primarily focused on volume over patient care.

Is ketamine therapy covered by insurance?

Spravato (esketamine nasal spray) is covered by many insurance plans because it has FDA approval. IV ketamine infusions are almost never covered by insurance because they are used off-label for depression. Some patients have success getting partial reimbursement by submitting superbills to their insurance company, and HSA/FSA accounts can generally be used for ketamine treatment. The ketamine therapy cost without insurance typically ranges from $2,400 to $4,800 for a standard initial series of six IV infusions.

The Bottom Line on Ketamine Therapy

Ketamine represents a genuine breakthrough in the treatment of depression, particularly for people who haven’t responded to conventional medications. The speed of its effects, the strength of the evidence for treatment-resistant depression and suicidal ideation, and its novel mechanism of action make it one of the most important developments in psychiatry in decades.

But it’s not a magic bullet. It requires ongoing treatment for most patients, it’s expensive (especially without insurance), the experience can be strange and disorienting, and the long-term effects of repeated use are still being studied. The evidence for conditions beyond treatment-resistant depression is promising but not yet definitive.

If you’re considering ketamine therapy, the most important steps you can take are: get a thorough evaluation from a qualified provider, understand the realistic expectations for your specific condition, choose a reputable clinic with proper medical oversight, and have a plan for integrating ketamine treatment with ongoing psychotherapy and self-care practices. The patients who tend to get the most from ketamine are those who use it as one part of a detailed treatment approach rather than a standalone solution.

Related Topics

Explore more about treatments that complement or relate to ketamine therapy:

• Psychedelic-Assisted Therapy – How other psychedelic-class substances like psilocybin and MDMA are being studied for mental health treatment
• Transcranial Magnetic Stimulation (TMS) – A non-invasive brain stimulation therapy often compared to ketamine for treatment-resistant depression
• Neurofeedback – Training the brain’s electrical activity patterns to improve mental health and cognitive function
• Float Therapy (Sensory Deprivation) – Reducing sensory input to promote deep relaxation and mental clarity
• Microdosing – Sub-perceptual doses of psychedelics explored for mood, creativity, and well-being
• Functional Medicine – A root-cause approach to health that often complements ketamine therapy for depression